Primer Capital
News
|
Drug for Ischemic Stroke Raises $15.3 million25 October 2018 Primer Capital’s portfolio company, Acticor Biotech (France), has closed a $15.3 million Series B round of financing from European and Asian investors. This funding will enable the company to finance the first Phase II of its antithrombotic drug for the acute phase of ischemic stroke.
|
|
|
|
Drug for Ischemic Stroke Raises $15.3 million Primer Capital’s portfolio company, Acticor Biotech (France), has closed a $15.3 million Series B round of financing from European and Asian investors. This funding will enable the company to finance the first Phase II of its antithrombotic drug for the acute phase of ischemic stroke.
|
|
Primer Capital Is the Best Venture Capitalist 201817 October 2018 Primer Capital was awarded the «Best investment at an early stage» within the contest «National VC Awards» for investing into Botkin.AI – the clinical decision support system based on artificial intelligence technologies.
|
|
|
|
Primer Capital Is the Best Venture Capitalist 2018 Primer Capital was awarded the «Best investment at an early stage» within the contest «National VC Awards» for investing into Botkin.AI – the clinical decision support system based on artificial intelligence technologies.
|
|
Primer Capital Invests in the Development of Molecular Bacteriotherapy of Atopic Dermatitis8 October 2018 Primer Capital Venture Fund invested $200K in California-based company MatriSys Bioscience. It is developing MSB-01, a commensal strain of bacteria S. hominis, that selectively kills an aggressive strain of Staphylococcus aureus that colonizes the skin of patients with atopic dermatitis (eczema). Moreover, MBS-01 helps to restore normal skin microbiome.
|
|
|
|
Primer Capital Invests in the Development of Molecular Bacteriotherapy of Atopic Dermatitis Primer Capital Venture Fund invested $200K in California-based company MatriSys Bioscience. It is developing MSB-01, a commensal strain of bacteria S. hominis, that selectively kills an aggressive strain of Staphylococcus aureus that colonizes the skin of patients with atopic dermatitis (eczema). Moreover, MBS-01 helps to restore normal skin microbiome.
|
|
Primer Capital’s portfolio company, Acticor Biotech announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited16 August 2018 Primer Capital’s portfolio company, Acticor Biotech, France – a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism - announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited, a wholly-owned subsidiary of China Medical System Holdings Limited ("CMS").
|
|
|
|
Primer Capital’s portfolio company, Acticor Biotech, France – a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism - announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited, a wholly-owned subsidiary of China Medical System Holdings Limited ("CMS").
|
|
Pilot implementation of Primer Capital’s portfolio project4 April 2018 Botkin.AI implements its AI-based clinical decision support system into a hospital located in the Murmansk Region.
|
|
|
|
Pilot implementation of Primer Capital’s portfolio project Botkin.AI implements its AI-based clinical decision support system into a hospital located in the Murmansk Region.
|
|
Startup Tour 20187 March 2018 60 proposals were submitted as part of the Skolkovo Startup Tour in Yuzhno-Sakhalinsk, of which 17 were approved for a face-to-face review.
|
|
|
|
60 proposals were submitted as part of the Skolkovo Startup Tour in Yuzhno-Sakhalinsk, of which 17 were approved for a face-to-face review.
|
|
February stock market decline for Big Pharma: panic or reality?27 February 2018 The beginning of February was marked by significant fluctuations in stock prices and indices at stock exchange markets. Vitaly Kolobov, Primer Capital’s Investment Project Manager, went into details of these changes.
|
|
|
|
February stock market decline for Big Pharma: panic or reality? The beginning of February was marked by significant fluctuations in stock prices and indices at stock exchange markets. Vitaly Kolobov, Primer Capital’s Investment Project Manager, went into details of these changes.
|
|
Private medical investments as industry growth drivers26 February 2018 Read the interview of Elizaveta Rozhdestvenskaya, Primer Capital’s COO, to the Medical News Agency.
|
|
|
|
Private medical investments as industry growth drivers Read the interview of Elizaveta Rozhdestvenskaya, Primer Capital’s COO, to the Medical News Agency.
|
|
TOP 3 most risky and promising areas of biotech7 February 2018 Primer Capital’s Investment Project Manager Vitaly Kolobov shared his view on some of the things that a “non-profile” investor should keep in mind when investing in biotech.
|
|
|
|
TOP 3 most risky and promising areas of biotech Primer Capital’s Investment Project Manager Vitaly Kolobov shared his view on some of the things that a “non-profile” investor should keep in mind when investing in biotech.
|
|
Why pharmaceutical companies abandon the development of important drugs?22 January 2018 Yuriy Chirgadze wrote a column about pharmaceutical companies closing their drug development programs that they have been investing in for many years.
|
|
|
|
Why pharmaceutical companies abandon the development of important drugs? Yuriy Chirgadze wrote a column about pharmaceutical companies closing their drug development programs that they have been investing in for many years.
|
Записи 1 - 10 of 24
First | Prev. | 1 2 3 | Next | Last